Citigroup’s NRC Health Common Stock NRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.2K Buy
659
+354
+116% +$6.02K ﹤0.01% 4992
2025
Q4
$5.72K Sell
305
-2,335
-88% -$35.2K ﹤0.01% 5209
2025
Q3
$33.7K Sell
2,640
-3,904
-60% -$58.5K ﹤0.01% 4618
2025
Q2
$110K Sell
6,544
-5,340
-45% -$72.1K ﹤0.01% 4358
2025
Q1
$152K Sell
11,884
-1,186
-9% -$19K ﹤0.01% 4347
2024
Q4
$231K Buy
13,070
+1,959
+18% +$37.2K ﹤0.01% 4332
2024
Q3
$254K Buy
11,111
+3,859
+53% +$87.2K ﹤0.01% 4179
2024
Q2
$166K Buy
7,252
+1,162
+19% +$35.8K ﹤0.01% 3982
2024
Q1
$241K Buy
6,090
+1,678
+38% +$66.4K ﹤0.01% 3919
2023
Q4
$175K Buy
4,412
+3,296
+295% +$138K ﹤0.01% 3969
2023
Q3
$49.5K Sell
1,116
-5,255
-82% -$229K ﹤0.01% 4142
2023
Q2
$277K Buy
6,371
+4,279
+205% +$188K ﹤0.01% 3727
2023
Q1
$91K Buy
2,092
+1,245
+147% +$55K ﹤0.01% 4054
2022
Q4
$31.6K Buy
847
+123
+17% +$4.76K ﹤0.01% 4429
2022
Q3
$29K Sell
724
-773
-52% -$28.6K ﹤0.01% 4602
2022
Q2
$57K Buy
1,497
+30
+2% +$1.08K ﹤0.01% 4479
2022
Q1
$59K Sell
1,467
-2,437
-62% -$95.4K ﹤0.01% 4655
2021
Q4
$162K Buy
3,904
+2,008
+106% +$87.3K ﹤0.01% 4465
2021
Q3
$80K Buy
1,896
+787
+71% +$39.6K ﹤0.01% 4501
2021
Q2
$51K Sell
1,109
-108
-9% -$5.14K ﹤0.01% 4817
2021
Q1
$57K Sell
1,217
-2,545
-68% -$124K ﹤0.01% 4633
2020
Q4
$161K Buy
3,762
+915
+32% +$47K ﹤0.01% 5152
2020
Q3
$140K Sell
2,847
-3,215
-53% -$178K ﹤0.01% 4867
2020
Q2
$353K Buy
6,062
+2,117
+54% +$112K ﹤0.01% 4565
2020
Q1
$179K Buy
3,945
+1,485
+60% +$89.2K ﹤0.01% 4828
2019
Q4
$162K Sell
2,460
-1,507
-38% -$92.1K ﹤0.01% 5366
2019
Q3
$229K Buy
3,967
+196
+5% +$12.1K ﹤0.01% 5048
2019
Q2
$217K Buy
3,771
+422
+13% +$19.5K ﹤0.01% 5189
2019
Q1
$129K Buy
3,349
+7
+0.2% +$274 ﹤0.01% 5510
2018
Q4
$127K Buy
3,342
+489
+17% +$18.8K ﹤0.01% 5451
2018
Q3
$110K Buy
2,853
+1,399
+96% +$53K ﹤0.01% 5809
2018
Q2
$54K Buy
1,454
+537
+59% +$18.7K ﹤0.01% 6225
2018
Q1
$26K Sell
917
-6,712
-88% -$225K ﹤0.01% 6597
2017
Q4
$285K Sell
7,629
-1,504
-16% -$53.4K ﹤0.01% 4701
2017
Q3
$344K Buy
9,133
+834
+10% +$26.2K ﹤0.01% 4494
2017
Q2
$224K Buy
8,299
+4,531
+120% +$111K ﹤0.01% 4692
2017
Q1
$74K Sell
3,768
-8,022
-68% -$148K ﹤0.01% 5431
2016
Q4
$224K Buy
11,790
+7,704
+189% +$127K ﹤0.01% 5187
2016
Q3
$67K Buy
4,086
+1,847
+82% +$29K ﹤0.01% 5466
2016
Q2
$31K Sell
2,239
-5,763
-72% -$81.2K ﹤0.01% 5872
2016
Q1
$124K Buy
8,002
+5,022
+169% +$73.6K ﹤0.01% 5505
2015
Q4
$47K Buy
2,980
+2,978
+148,900% +$45.2K ﹤0.01% 5986
2015
Q3
$0 Sell
2
-1,145
-100% -$15.2K ﹤0.01% 7596
2015
Q2
$16K Buy
1,147
+603
+111% +$8.54K ﹤0.01% 6219
2015
Q1
$8K Sell
544
-1,158
-68% -$16.4K ﹤0.01% 6553
2014
Q4
$24K Buy
1,702
+1,355
+390% +$19.9K ﹤0.01% 6128
2014
Q3
$5K Buy
347
+263
+313% +$3.62K ﹤0.01% 6561
2014
Q2
$1K Sell
84
-5,722
-99% -$86.1K ﹤0.01% 6935
2014
Q1
$96K Buy
5,806
+776
+15% +$13K ﹤0.01% 5029
2013
Q4
$95K Buy
5,030
+3,949
+365% +$69.3K ﹤0.01% 5294
2013
Q3
$20K Sell
1,081
-1,538
-59% -$26.4K ﹤0.01% 5913
2013
Q2
$47K Buy
+2,619
New +$41.8K ﹤0.01% 5407

Other funds holding NRC

Citigroup's NRC Position: Q1 2026 in Review

Citigroup increased its NRC Health Common Stock (NRC) stake by 116% in Q1 2026, buying an estimated $6.02K and bringing the position to 659 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4992.

Citigroup first reported a position in NRC in Q2 2013 and has held it in 52 quarters since. The position peaked at $353K in Q2 2020. 121 funds tracked by Wall St. Rank hold NRC as of Q1 2026.

  • Citigroup held 659 shares of NRC Health Common Stock worth $11.2K as of Q1 2026.
  • Citigroup bought 354 NRC Health Common Stock shares in Q1 2026, an estimated $6.02K.
  • NRC Health Common Stock made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4992 holding.
  • Citigroup first reported a position in NRC Health Common Stock in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's NRC Health Common Stock position peaked at $353K in Q2 2020.
  • 121 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.